Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Reimbursement News » CareDx Stock Spikes on News of MolDX Reimbursement of AlloSure

CareDx Stock Spikes on News of MolDX Reimbursement of AlloSure

Sep 26, 2017
|
staff reporter

NEW YORK (GenomeWeb) – CareDx's shares soared as high as 34 percent in morning trading on the Nasdaq after the company announced that Palmetto GBA's Molecular Diagnostics Services (MolDX) Program had set reimbursement for the firm's AlloSure cfDNA-based organ transplant test diagnostic at $2,840.75.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.